Baricitinib (Rheumatoid Arthritis) Market - Size, Share, Trends, Company
Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,
Segmentation and Forecast To 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and
deformity of the joints . It affects over seven million individuals in the 10MM covered in this
report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the
prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have
been effective in treating the signs and symptoms of RA and inhibiting progression to erosive
bone disease. However, the landscape is quickly changing with the introduction of biosimilars,
novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change
the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective
therapies for RA, the market is extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Eli Lilly and Incyte are jointly developing baricitinib, an oral JAK inhibitor, for the treatment of
patients with moderate to severe RA. Baricitinib has roughly equal affinity for JAK1 and JAK2,
preventing the intracellular signaling cascades that lead to the production of IL-6 and IL-23,
thereby reducing inflammation.
Complete report is available at: https://www.radiantinsights.com/research/baricitinib-
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Baricitini